CONFERENCE DAY TWO
June 13, 2024
8:30 am Check In & Coffee
8:55 am Chair’s Opening Remark
Exploring Strategies to Ensure Weight Maintenance
9:00 am Unveiling Trial Related Considerations For Late-Stage Development Of Incretin-Based Therapies
Synopsis
- Leveraging experience in the field and with phase 3 incretin trials at Lilly to explore latestage obesity drug development
- Investigating patient safety in trials which are driving the standard of care
- Driving forward innovation in obesity trials
9:30 am Navigating the Need to Circumvent Weight Cycling
Synopsis
- Inspecting approaches to avoid the rebound effect and unlock long term results
- Optimizing weight management from a GLP-1 perspective: combatting GLP associated challenges of decrease in energy expenditure
- Unveiling the impact of fibrosis, muscle and fat homeostasis
10:00 am Morning Break & Networking
10:45 am Analyzing Real-World Evidence on the Usage of GLP-1 Class Drugs, Regarding Efficacy and Adherence
Synopsis
- Leveraging Real-World Evidence of the usage of GLP-1 Class drugs on patient behaviors, experience and adherence patterns
- Sharing progress and lessons learned from marketed anti-obesity drugs
- Exploring new therapeutic directions and future precision medicine for anti-obesity drugs
11:15 am Panel Discussion & Extended Q&A: Exploring Standardization, the Alignment of Endpoints with Regulatory Standards, & Avoiding Weight Cycling with New Obesity Treatments
11:45 am Lunch Break & Networking
Moving Beyond Incretins: Future Directions & Emerging Approaches
12:45 pm Showcasing Novel Liver-Targeted Mitochondrial Protonophores Approach for the Treatment of Obesity and Diabetes
Synopsis
- Leveraging mitochondrial uncoupling with synthetic protonophores as a clinically validated mechanism for weight loss
- Overcoming hyperthermia due to uncontrolled systemic uncoupling which has limited clinical development of synthetic protonophores
- Outlining pioneering efforts from OrsoBio which have created a portfolio of synthetic protonophores that demonstrate enhanced therapeutic margins owing to their livertargeted pharmacology
1:15 pm Shedding Light on Gut-Driven Mechanisms for Rethinking Targets in Disease Modification
Synopsis
- Investigating the involvement of gut microbiota in the dysfunction of beta cells and development of insulin resistance
- Revealing the potential of gut signalling as a means for modifying diseases and identifying specific gut targets informed by insights from bariatric surgery
- Spearheading the development of innovative gut-targeted polymer therapies aimed at enhancing blood glucose levels
1:45 pm Afternoon Break & Networking
2:30 pm Evaluating Clinical Promising Oral Obesity Drugs
Synopsis
- Determining synergistic combinations with GLP-1Ras with potentially complementary MoAs
- Delving into PON2 a ubiquitously expressed protein localised in the ER and mitochondria of many organs
- Demonstrating fat-selective weight loss in obese mouse models through a first in class PON2 modulator which activates autophagy